LGVN

Longeveron is a pre-commercial, clinical-stage biotech whose entire value rests on one investigational asset, laromestrocel, across three unapproved indications (HLHS, Alzheimer's, pediatric DCM). There is no product business here: FY2025 'revenue' of $1.20M is NIH/NIA grant income, it fell 49.9% YoY, and against it the company burned -$18.6M in operating cash and posted a -$22.7M net loss. The auditor issued a going-concern emphasis-of-matter paragraph, and management states cash of $4.7M plus $15.9M of March-2026 private-placement gross proceeds funds operations only 'into the fourth quarter of 2026.' That is roughly a year of runway for a company that must run expensive Phase 2b/registrational trials — meaning another raise is a near-certainty, not a risk.

The balance sheet is depleting fast: total assets -59.9%, cash -75.8%, stockholders' equity -74.1% to just $5.67M, and an accumulated deficit of $132M that grows every quarter. The financing structure is punishing to common holders. The 10-K discloses 21.9M warrants outstanding (as low as $0.85), an ATM with H.C. Wainwright, an August 2025 offering priced at $0.85, and a March 2026 private placement at $0.52/share plus Series A preferred convertible into ~22.8M shares — and Longeveron even sold away 50% of the economics of a potential HLHS Rare Pediatric Disease Priority Review Voucher. The second tranche (~$15M) is gated on hitting a statistically significant HLHS Phase 2b endpoint AND the stock trading ≥$1.85 on heavy volume — conditions the current $0.69 price is nowhere near. This is a company financing itself by continuously selling the future.